Integrative multi-omics Mendelian randomization reveals key lipid metabolism genes as therapeutic targets for diabetic nephropathy pathogenesis.
Genetically predicted higher expression of CERS2 and MED27 is linked to increased risk of diabetic nephropathy, but their expression patterns may indicate complex regulatory mechanisms.
Where it sits
this study against the rest of the melanotan ii corpusSummary and findings
This study identified lipid metabolism genes associated with diabetic nephropathy (DN) risk using summary-data-based Mendelian randomization. Key genes prioritized include CERS2, MED27, and PLA2G1B, with genetically predicted higher expression of CERS2 (OR = 1.246, p_SMR = 0.027) and MED27 (OR = 1.551, p_SMR = 0.032) linked to increased DN risk. The findings suggest complex regulatory mechanisms affecting gene expression and DN risk.
Abstract
Dysregulated lipid metabolism contributes to diabetic nephropathy (DN), but the genetic links remain unclear. This study identified lipid metabolism genes associated with DN risk using summary-data-based Mendelian randomization (SMR). SMR screened 757 lipid metabolism genes by integrating large-scale blood methylation quantitative trait locus (mQTL; <i>n</i> = 1,980), expression QTL (eQTL; <i>n</i> = 31,684), and protein QTL (pQTL; <i>n</i> = 54,219) datasets with FinnGen genome-wide association study (5,042 cases/79,344 controls), followed by validation in GCST005881 (5,908 cases/4,967 controls). Functional enrichment, protein-protein interaction, and mQTL-eQTL integration were performed. Nephroseq data were used to examine tissue-level expression-renal function correlations. External bulk and single-cell transcriptomic datasets were analyzed to assess stage- and cell-type-specific expression. <i>CERS2, MED27,</i> and <i>PLA2G1B</i> were prioritized as DN-associated risk genes. Genetically predicted higher expression of <i>CERS2</i> (OR = 1.246, p_SMR = 0.027) and <i>MED27</i> (OR = 1.551, p_SMR = 0.032) increased DN risk. Methylation at cg26058502 (<i>CERS2:</i> OR = 0.604, FDR = 1.61 × 10-23) and cg13628444 (<i>MED27</i>: OR = 0.662, FDR = 3.82 × 10<sup>-10</sup>) demonstrated negative regulatory effects on gene expression. <i>PLA2G1B</i> was linked to increased risk at methylation (cg16396488: OR = 1.369, p_SMR = 7.82 × 10<sup>-4</sup>) and protein (OR = 3.057, p_SMR = 0.005) levels. However, in the Nephroseq database, higher expression of all three genes correlated with better kidney function. External bulk transcriptomics showed transient upregulation of <i>CERS2</i> and <i>MED27</i> in early DN but not advanced stages. <i>PLA2G1B</i> exhibited no differential expression or association with renal function. Single-cell analysis demonstrated broad detection of <i>CERS2</i> and <i>MED27</i> across renal cell types with subset enrichment, whereas <i>PLA2G1B</i> expression was sparse, with no evident disease-associated shifts. These findings indicate discordance between genetically inferred risk effects and observed expression patterns, suggesting complex regulatory mechanisms.
Background
Dysregulated lipid metabolism is implicated in diabetic nephropathy (DN), but the genetic connections have not been fully elucidated. Previous studies have identified various risk factors for DN, yet the specific lipid metabolism genes involved remain unclear. This study aims to clarify these associations using a Mendelian randomization approach, which integrates multiple large-scale datasets.
Methods
The study utilized summary-data-based Mendelian randomization (SMR) to screen 757 lipid metabolism genes. The analysis included large-scale datasets: blood methylation quantitative trait locus (mQTL; n=1,980), expression QTL (eQTL; n=31,684), and protein QTL (pQTL; n=54,219), alongside the FinnGen genome-wide association study (5,042 cases/79,344 controls). Validation was performed in the GCST005881 dataset (5,908 cases/4,967 controls).
Results
The primary endpoint identified CERS2 and MED27 as risk genes for DN, with genetically predicted higher expression linked to increased risk (CERS2: OR = 1.246, p_SMR = 0.027; MED27: OR = 1.551, p_SMR = 0.032). Methylation at specific sites negatively regulated gene expression, while higher expression of all three genes correlated with better kidney function in the Nephroseq database. PLA2G1B was associated with increased risk at both methylation and protein levels.
Interpretation
The findings indicate that while genetically predicted expression of CERS2 and MED27 is associated with increased DN risk, their expression patterns suggest a more complex relationship with kidney function. This discordance raises questions about the clinical significance of these genetic associations. The study's reliance on genetic data and the absence of direct causative evidence limit the conclusions that can be drawn regarding therapeutic targets.
Key findings
- CERS2: OR = 1.246, p_SMR = 0.027
- MED27: OR = 1.551, p_SMR = 0.032
- CERS2 methylation at cg26058502: OR = 0.604, FDR = 1.61 × 10-23
- MED27 methylation at cg13628444: OR = 0.662, FDR = 3.82 × 10-10
- PLA2G1B methylation at cg16396488: OR = 1.369, p_SMR = 7.82 × 10-4
- PLA2G1B protein level: OR = 3.057, p_SMR = 0.005
Limitations
- Not reported in abstract.
- Study relies on genetic associations, not direct causation.
- Complex regulatory mechanisms may limit interpretation.
- Not reported in abstract.